株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全身性紅斑性狼瘡 (SLE):パイプライン製品の分析

Systemic Lupus Erythematosus - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 264101
出版日 ページ情報 英文 427 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
全身性紅斑性狼瘡 (SLE):パイプライン製品の分析 Systemic Lupus Erythematosus - Pipeline Review, H2 2017
出版日: 2017年11月14日 ページ情報: 英文 427 Pages
概要

全身性紅斑性狼瘡 (SLE) は、慢性的な炎症性疾患の原因となる自己免疫疾患です。SLEが原因の炎症によって、皮膚や関節、腎臓、脳などの様々な器官が影響を受けます。様々な要因が遺伝、環境、性、ホルモンなどの疾患と関係しています。症侯は様々で、時間とともに変化しますが、一般的なものとして重度の疲労感、関節の痛みや腫れ、頭痛、蝶形紅斑と呼ばれる頬や鼻の発疹、抜け毛、貧血などがあります。

当レポートでは、全身性紅斑性狼瘡 (SLE) の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

全身性紅斑性狼瘡の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9879IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 28, 25, 40, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Lupus Erythematosus - Overview
    • Systemic Lupus Erythematosus - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Systemic Lupus Erythematosus - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Ablynx NV
    • ACEA Biosciences Inc
    • AiCuris GmbH & Co KG
    • Amgen Inc
    • Asahi Kasei Pharma Corp
    • Atlantic Bio Sci LLC
    • Aurinia Pharmaceuticals Inc
    • Bio-Path Holdings Inc
    • Biogen Inc
    • Biotest AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Co
    • Celgene Corp
    • Corestem Inc
    • CuraVac Inc
    • Deltanoid Pharmaceuticals Inc
    • Domainex Ltd
    • Eisai Co Ltd
    • Eli Lilly and Co
    • F. Hoffmann-La Roche Ltd
    • Galapagos NV
    • Genentech Inc
    • Genosco Inc
    • Genovax Srl
    • Gilead Sciences Inc
    • GlaxoSmithKline Plc
    • HanAll Biopharma Co Ltd
    • Hanmi Pharmaceuticals Co Ltd
    • Idorsia Ltd
    • Immungenetics AG
    • Immunomedics Inc
    • Immunwork Inc
    • Immupharma Plc
    • Invion Ltd
    • Janus Biotherapeutics Inc
    • Johnson & Johnson
    • K-Stemcell Co Ltd
    • Karyopharm Therapeutics Inc
    • KPI Therapeutics Inc
    • Kyowa Hakko Kirin Co Ltd
    • Lead Discovery Center GmbH
    • LSK BioPartners Inc
    • MacroGenics Inc
    • MedAnnex Ltd
    • Medestea Research & Production SpA
    • MedImmune LLC
    • Merck & Co Inc
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Mitsubishi Tanabe Pharma Corp
    • Mount Tam Biotechnologies Inc
    • Nektar Therapeutics
    • Neovacs SA
    • Nippon Chemiphar Co Ltd
    • Novartis AG
    • Nuevolution AB
    • Omeros Corp
    • Pfizer Inc
    • Principia Biopharma Inc
    • Ra Pharmaceuticals Inc
    • RedHill Biopharma Ltd
    • Sarepta Therapeutics Inc
    • SBI Biotech Co Ltd
    • Takeda Pharmaceutical Co Ltd
    • TheraMAB LLC
    • TxCell SA
    • UCB SA
    • Xencor Inc
    • XTL Biopharmaceuticals Ltd
    • Zai Lab Ltd
  • Systemic Lupus Erythematosus - Drug Profiles
    • (clarithromycin + clofazimine + rifabutin) - Drug Profile
    • abatacept - Drug Profile
    • ABS-11 - Drug Profile
    • AC-058 - Drug Profile
    • ACY-1083 - Drug Profile
    • ACY-738 - Drug Profile
    • aldesleukin - Drug Profile
    • aldesleukin - Drug Profile
    • AMG-557 - Drug Profile
    • AMG-570 - Drug Profile
    • amiselimod hydrochloride - Drug Profile
    • anifrolumab - Drug Profile
    • Annexuzlimab - Drug Profile
    • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
    • APT-602 - Drug Profile
    • AT-791 - Drug Profile
    • atacicept - Drug Profile
    • baricitinib - Drug Profile
    • bee venom [Apis mellifera] allergen extract - Drug Profile
    • belimumab - Drug Profile
    • belimumab + rituximab - Drug Profile
    • BI-655064 - Drug Profile
    • BI-705564 - Drug Profile
    • BIIB-059 - Drug Profile
    • BIIB-068 - Drug Profile
    • Bispecific Monoclonal Antibody to Inhibit CD22 and CD20 for Autoimmune Disorders and Oncology - Drug Profile
    • BL-5923 - Drug Profile
    • BMS-986165 - Drug Profile
    • bortezomib - Drug Profile
    • BT-063 - Drug Profile
    • C-15231A - Drug Profile
    • CC-90008 - Drug Profile
    • Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile
    • Cellular Immunotherapy for Epstein-Barr Viral Infections, Multiple Sclerosis and Systemic Lupus Erythematosus - Drug Profile
    • Cellular Immunotherapy to Target CD19 for Oncology and Immunology - Drug Profile
    • cenerimod - Drug Profile
    • CS-20AT04 - Drug Profile
    • dalazatide - Drug Profile
    • dapirolizumab pegol - Drug Profile
    • DMXD-011 - Drug Profile
    • DP-001 - Drug Profile
    • Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
    • Drugs to Inhibit BAFF and APRIL for Systemic Lupus Erythematosus - Drug Profile
    • E-6446 - Drug Profile
    • edratide - Drug Profile
    • ENTX-LN - Drug Profile
    • evobrutinib - Drug Profile
    • faralimomab - Drug Profile
    • filgotinib - Drug Profile
    • forigerimod acetate - Drug Profile
    • GDC-0853 - Drug Profile
    • GNKS-356 - Drug Profile
    • GS-9876 - Drug Profile
    • GX-101 - Drug Profile
    • HCI-1401 - Drug Profile
    • HE-33 - Drug Profile
    • HL-161 - Drug Profile
    • iberdomide hydrochloride - Drug Profile
    • ICP-022 - Drug Profile
    • IL-233 - Drug Profile
    • IMP-10 - Drug Profile
    • INV-103 - Drug Profile
    • INV-17 - Drug Profile
    • INV-88 - Drug Profile
    • ixazomib citrate - Drug Profile
    • JB-6121 - Drug Profile
    • JNJ-0839 - Drug Profile
    • JNJ-56022473 - Drug Profile
    • KPT-350 - Drug Profile
    • lenabasum - Drug Profile
    • lulizumab pegol - Drug Profile
    • MEDI-7734 - Drug Profile
    • MGD-010 - Drug Profile
    • milatuzumab - Drug Profile
    • mizoribine - Drug Profile
    • NC-2400 - Drug Profile
    • NCS-613 - Drug Profile
    • NKTR-358 - Drug Profile
    • NUE-7770 - Drug Profile
    • obinutuzumab - Drug Profile
    • OMS-721 - Drug Profile
    • P-Dex - Drug Profile
    • PF-06823859 - Drug Profile
    • poseltinib - Drug Profile
    • prexigebersen - Drug Profile
    • PRN-1008 - Drug Profile
    • RA-101495 - Drug Profile
    • RCT-18 - Drug Profile
    • RSLV-132 - Drug Profile
    • RSLV-133 - Drug Profile
    • SBI-9674 - Drug Profile
    • SKIO-703 - Drug Profile
    • SM-03 - Drug Profile
    • SM-934 - Drug Profile
    • Small Molecule to Agonize CD11b for Systemic Lupus Erythematosus - Drug Profile
    • Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
    • Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile
    • Small Molecules for Respiratory and Immunology - Drug Profile
    • Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile
    • Small molecules to Inhibit PAD for Autoimmune Diseases, Multiple Sclerosis and Oncology - Drug Profile
    • Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile
    • Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    • Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile
    • TAB-08 - Drug Profile
    • TAK-079 - Drug Profile
    • TAM-01 - Drug Profile
    • TE-2324 - Drug Profile
    • tofacitinib citrate - Drug Profile
    • ustekinumab - Drug Profile
    • Vaccine for Systemic Lupus Erythematosus - Drug Profile
    • Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
    • venetoclax - Drug Profile
    • VISTA-Ig - Drug Profile
    • vobarilizumab - Drug Profile
    • voclosporin - Drug Profile
    • WITH-1101 - Drug Profile
    • XL-499 - Drug Profile
    • XmAb-5871 - Drug Profile
    • ZL-1101 - Drug Profile
  • Systemic Lupus Erythematosus - Dormant Projects
  • Systemic Lupus Erythematosus - Discontinued Products
  • Systemic Lupus Erythematosus - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Lupus Erythematosus, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by MacroGenics Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production SpA, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Novartis AG, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2017
  • Systemic Lupus Erythematosus - Pipeline by Zai Lab Ltd, H2 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Systemic Lupus Erythematosus - Discontinued Products, H2 2017
  • Systemic Lupus Erythematosus - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Systemic Lupus Erythematosus, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top